



SAFETY DATA SHEET

Revision date 30-Jun-2022

Version 1.01

Page 1 / 14

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Clindamycin phosphate injection, solution (Hospira, Inc.)
Product Code(s) PZ03369
Synonyms PNU-28508E
Trade Name: Not applicable
Chemical Family: Mixture

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product used as antibiotic agent

1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited
Horizon
Honey Lane
Hurley
Maidenhead, SL6 6RJ
United Kingdom

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

Skin corrosion/irritation Category 3
Serious eye damage/eye irritation Category 2A
Skin sensitization Category 1

2.2. Label elements

Signal word Warning

Hazard statements
H319 - Causes serious eye irritation
H316 - Causes mild skin irritation
H317 - May cause an allergic skin reaction

Precautionary Statements
P261 - Avoid breathing dust/fume/gas/mist/vapors/spray
P264 - Wash hands thoroughly after handling
P272 - Contaminated work clothing must not be allowed out of the workplace
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P302+ P352 - IF ON SKIN: Wash with plenty of soap and water
P333 + P313 - If skin irritation or rash occurs: Get medical advice/attention

SAFETY DATA SHEET

Product Name Clindamycin phosphate injection, solution (Hospira, Inc.)
Revision date 30-Jun-2022

Page 2 / 14
Version 1.01

P363 - Wash contaminated clothing before reuse
P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes.
Remove contact lenses, if present and easy to do. Continue rinsing
P337 + P313 - If eye irritation persists: Get medical advice/attention
P501 - Dispose of contents/container in accordance with all local and national regulations



2.3. Other hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances

Not applicable

3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Clindamycin Phosphate (CAS #: 24729-96-2)	15		246-433-0	Acute Tox.4 (H302) Eye Irrit.2A (H319) Skin Irrit.3 (H316) Skin Sens.1 (H317)	Not Listed	No data available	No data available
BENZYL ALCOHOL (CAS #: 100-51-6)	<1.0		202-859-9	Acute Tox. 4 (H302) Acute Tox. 4 (H332)	Not Listed	No data available	No data available
Sodium hydroxide (CAS #: 1310-73-2)	**	-	215-185-5	Skin Corr.1A (H314)	Eye Irrit. 2 :: 0.5%<=C<2% Skin Corr. 1A :: C>=5% Skin Corr. 1B :: 2%<=C<5% Skin Irrit. 2 :: 0.5%<=C<2%	No data available	No data available

SAFETY DATA SHEET

Product Name Clindamycin phosphate injection, solution (Hospira, Inc.)
Revision date 30-Jun-2022

Page 3 / 14
Version 1.01

+ Hydrochloric Acid (CAS #: 7647-01-0)	**	-	231-595-7	Acute Tox. 3 (H331) Skin Corr. 1A (H314) Press. Gas	Eye Irrit. 2 :: 10%≤C<25% Skin Corr. 1B :: C≥25% Skin Irrit. 2 :: 10%≤C<25% STOT SE 3 :: C≥10%	No data available	No data available
---	----	---	-----------	---	---	----------------------	----------------------

NonHazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Water (CAS #: 7732-18-5)	*	-	231-791-2	Not classified as hazardous	Not Listed	No data available	No data available

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate

No information available

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
Clindamycin Phosphate 24729-96-2	1832	No data available	No data available	No data available	No data available
BENZYL ALCOHOL 100-51-6	1230	2000	4.178	No data available	No data available
Sodium hydroxide 1310-73-2	325	1350	No data available	No data available	No data available
+ Hydrochloric Acid 7647-01-0	238	5010	No data available	No data available	563.3022

Additional information

* Proprietary

** to adjust pH

+ Substance with a Union workplace exposure limit

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret. Non-hazardous ingredients provided for completeness.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation

Remove to fresh air. Seek immediate medical attention/advice.

Eye contact

Flush with water while holding eyelids open for at least 15 minutes. If irritation occurs or persists, get medical attention.

Skin contact

Remove contaminated clothing and wash exposed area with soap and water. Obtain medical assistance if irritation occurs.

SAFETY DATA SHEET

Product Name Clindamycin phosphate injection, solution (Hospira, Inc.)
Revision date 30-Jun-2022

Page 4 / 14
Version 1.01

Ingestion

Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects

For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians

None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media

Dry chemical, CO2, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical

Fine particles (such as dust and mists) may fuel fires/explosions.

Hazardous combustion products

Formation of toxic gases is possible during heating or fire.

5.3. Advice for firefighters

Special protective equipment for fire-fighters

Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

For emergency responders

Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Methods for cleaning up

Prevent further leakage or spillage if safe to do so.
Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Prevention of secondary hazards

Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections

See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

SAFETY DATA SHEET

Product Name Clindamycin phosphate injection, solution (Hospira, Inc.)
Revision date 30-Jun-2022

Page 5 / 14
Version 1.01

Advice on safe handling

Avoid breathing mist or aerosols. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s) Pharmaceutical drug product.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Clindamycin Phosphate

Pfizer OEL TWA-8 Hr: 100 µg/m³

BENZYL ALCOHOL

Pfizer OEL TWA-8 Hr: 10 ppm

BENZYL ALCOHOL

Bulgaria

5.0 mg/m³

Czech Republic

40 mg/m³

Ceiling: 80 mg/m³

Finland

10 ppm

45 mg/m³

Germany

22 mg/m³ can occur as vapor and aerosol at the same time

5 ppm can occur as vapor and aerosol at the same time

Ceiling / Peak: 44 mg/m³

Ceiling / Peak: 10 ppm

Skin

Germany

5 ppm

22 mg/m³

H*

Ceiling Limit Value

25 mg/m³

Latvia

5 mg/m³

Poland

240 mg/m³

Russia

MAC: 5 mg/m³

Skin

Switzerland

5 ppm

22 mg/m³

H*

Sodium hydroxide

ACGIH OEL (Ceiling)

2 mg/m³

ACGIH TLV

Ceiling: 2 mg/m³

Austria

2 mg/m³

STEL 4 mg/m³

Bulgaria

2.0 mg/m³

Czech Republic

1 mg/m³

Ceiling: 2 mg/m³

Denmark

Ceiling: 2 mg/m³

Estonia

1 mg/m³

STEL: 2 mg/m³

SAFETY DATA SHEET

Product Name Clindamycin phosphate injection, solution (Hospira, Inc.)
Revision date 30-Jun-2022

Page 6 / 14
Version 1.01

Finland	Ceiling: 2 mg/m ³
France	2 mg/m ³
Hungary	1 mg/m ³
	STEL: 2 mg/m ³
Ireland	STEL: 2 mg/m ³
Ceiling Limit Value	2 mg/m ³
Latvia	0.5 mg/m ³
Poland	STEL: 1 mg/m ³
	0.5 mg/m ³
Romania	1 mg/m ³
	STEL: 3 mg/m ³
Slovakia	2 mg/m ³
Spain	STEL: 2 mg/m ³
Switzerland	2 mg/m ³
	STEL: 2 mg/m ³
OSHA PEL	2 mg/m ³
United Kingdom	(vacated) Ceiling: 2 mg/m ³
+ Hydrochloric Acid	STEL: 2 mg/m ³
ACGIH OEL (Ceiling)	2 ppm
ACGIH TLV	Ceiling: 2 ppm
Austria	5 ppm
	8 mg/m ³
	STEL 10 ppm
	STEL 15 mg/m ³
Bulgaria	STEL: 10 ppm
	STEL: 15.0 mg/m ³
	5 ppm
	8.0 mg/m ³
Czech Republic	8 mg/m ³
	Ceiling: 15 mg/m ³
Estonia	5 ppm
	8 mg/m ³
	STEL: 10 ppm
	STEL: 15 mg/m ³
European Union	TWA: 5 ppm
	TWA: 8 mg/m ³
	STEL: 10 ppm
	STEL: 15 mg/m ³
Finland	STEL: 5 ppm
	STEL: 7.6 mg/m ³
Germany	2 ppm
	3.0 mg/m ³
	Ceiling / Peak: 4 ppm
	Ceiling / Peak: 6 mg/m ³
Germany	2 ppm
	3 mg/m ³
Hungary	8 mg/m ³
	STEL: 16 mg/m ³
Ireland	8 mg/m ³
	5 ppm
	STEL: 10 ppm
	STEL: 15 mg/m ³
Italy	5 ppm
	8 mg/m ³
	STEL: 10 ppm
	STEL: 15 mg/m ³
Ceiling Limit Value	2 ppm
	3.0 mg/m ³
Latvia	5 ppm

SAFETY DATA SHEET

Product Name Clindamycin phosphate injection, solution (Hospira, Inc.)
Revision date 30-Jun-2022

Page 7 / 14
Version 1.01

	8 mg/m ³ STEL: 10 ppm STEL: 15 mg/m ³
Netherlands	8 mg/m ³ STEL: 15 mg/m ³
Poland	STEL: 10 mg/m ³ 5 mg/m ³
Romania	5 ppm 8 mg/m ³ STEL: 10 ppm STEL: 15 mg/m ³
Russia	MAC: 5 mg/m ³
Slovakia	5 ppm 8.0 mg/m ³
Spain	5 ppm 7.6 mg/m ³ STEL: 10 ppm STEL: 15 mg/m ³
Switzerland	2 ppm 3 mg/m ³ STEL: 4 ppm STEL: 6 mg/m ³
U.S. - OSHA - Final PELs - Ceiling Limits	5 ppm 7 mg/m ³
OSHA PEL	(vacated) Ceiling: 5 ppm (vacated) Ceiling: 7 mg/m ³ Ceiling: 5 ppm Ceiling: 7 mg/m ³
United Kingdom	TWA: 1 ppm TWA: 2 mg/m ³ STEL: 5 ppm STEL: 8 mg/m ³

8.2. Exposure controls

Engineering controls	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
Environmental exposure controls	No information available.
Personal protective equipment	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.
Eye/face protection	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).
Hand protection	Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).
Skin and body protection	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).
Respiratory protection	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control

SAFETY DATA SHEET

Product Name Clindamycin phosphate injection, solution (Hospira, Inc.)
Revision date 30-Jun-2022

Page 8 / 14
Version 1.01

exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter).
(Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state	Solution
Color	Clear, colorless
Odor	No information available.
Odor threshold	No information available
Molecular formula	Mixture
Molecular weight	Mixture

Property	Values
pH	No data available
Melting point / freezing point	No data available
Boiling point / boiling range	
Flash point	No information available
Evaporation rate	No data available
Flammability (solid, gas)	No data available
Flammability Limit in Air	
Upper flammability limit:	No data available
Lower flammability limit:	No data available
Vapor pressure	No data available
Vapor density	No data available
Relative density	No data available
Water solubility	No data available
Solubility(ies)	No data available
Partition coefficient	No data available
Autoignition temperature	No data available
Decomposition temperature	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available
Explosive properties	No information available

9.2. Other information

No information available

9.2.1. Information with regard to physical hazard classes

No information available

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

SAFETY DATA SHEET

Product Name Clindamycin phosphate injection, solution (Hospira, Inc.)
Revision date 30-Jun-2022

Page 9 / 14
Version 1.01

Reactivity No data available.

10.2. Chemical stability

Stability Stable under normal conditions.

Explosion data

Sensitivity to Mechanical Impact No data available.

Sensitivity to Static Discharge No data available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

Conditions to avoid Fine particles (such as dust and mists) may fuel fires/explosions.

10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information: The information included in this section describes the potential hazards of the individual ingredients

Short term Active ingredient may be harmful if swallowed. May cause eye irritation. May cause skin irritation (based on components).

Known Clinical Effects: Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Clinical use of this drug has caused sore throat, fever, gastrointestinal disturbances, abnormal liver function tests, kidney dysfunction. Pseudomembranous colitis (manifested by watery diarrhea, urge to defecate, abdominal cramps, low-grade fever, bloody stools, and abdominal pain) may also occur.

Acute toxicity Based on available data, the classification criteria are not met.

Serious eye damage/eye irritation Classification is based on mixture calculation methods based on component data.

Skin corrosion/irritation Classification is based on mixture calculation methods based on component data.

Respiratory or skin sensitization Classification is based on mixture calculation methods based on component data.

STOT - single exposure Based on available data, the classification criteria are not met.

STOT - repeated exposure Based on available data, the classification criteria are not met.

Reproductive toxicity Based on available data, the classification criteria are not met.

Germ cell mutagenicity Based on available data, the classification criteria are not met.

Carcinogenicity Based on available data, the classification criteria are not met.

Aspiration hazard Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)

Clindamycin Phosphate

Rat Oral LD 50 1832 mg/kg
Rat Para-periosteal LD 50 321 mg/kg
Rat Intraperitoneal LD 50 745 mg/kg
Mouse Oral LD 50 2359 mg/kg
Mouse Intravenous LD 50 820 mg/kg

BENZYL ALCOHOL

Rat Oral LD 50 1230 mg/kg
Mouse Oral LD 50 1360 mg/kg
Rabbit Dermal LD 50 2 gm/kg

Edetate disodium

Rat Oral LD50 2000-2200 mg/kg

Sodium hydroxide

Mouse IP LD50 40 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg (Rat)	-	-

SAFETY DATA SHEET

Product Name Clindamycin phosphate injection, solution (Hospira, Inc.)
Revision date 30-Jun-2022

Page 10 / 14
Version 1.01

Clindamycin Phosphate	= 1832 mg/kg (Rat)	-	-
BENZYL ALCOHOL	= 1230 mg/kg (Rat)	= 2 g/kg (Rabbit)	> 4178 mg/m ³ (Rat) 4 h
Sodium hydroxide	= 325 mg/kg (Rat)	= 1350 mg/kg (Rabbit)	-
+ Hydrochloric Acid	238 - 277 mg/kg (Rat)	> 5010 mg/kg (Rabbit)	= 1.68 mg/L (Rat) 1 h

Irritation / Sensitization: (Study Type, Species, Severity)

Clindamycin Phosphate

Eye Irritation Rabbit Moderate

Skin Irritation Rabbit Mild

BENZYL ALCOHOL

Eye Irritation Rabbit Severe

Skin Irritation Rabbit Minimal

Skin Irritation Guinea Pig Moderate

Sodium hydroxide

Eye Irritation Rabbit Severe

Skin Irritation Rabbit Severe

+ Hydrochloric Acid

Skin irritation Severe

Eye irritation Severe

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Clindamycin Phosphate

6 Month(s) Rat Oral 600 mg/kg/day NOAEL No effects at maximum dose

6 Month(s) Dog Oral 600 mg/kg/day NOAEL Gastrointestinal system

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Clindamycin Phosphate

Prenatal & Postnatal Development Rat Subcutaneous 250 mg/kg NOAEL Not teratogenic

Prenatal & Postnatal Development Rat Oral 300 mg/kg/day NOAEL Not Teratogenic

Prenatal & Postnatal Development Mouse Oral 600 mg/kg/day NOAEL Not Teratogenic

Prenatal & Postnatal Development Rabbit Subcutaneous 5 mg/kg/day NOAEL Not Teratogenic, Maternal Toxicity

Reproductive & Fertility Rat Oral 300 mg/kg/day NOAEL No effects at maximum dose

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Clindamycin Phosphate

Bacterial Mutagenicity (Ames) *Salmonella* Negative

In Vitro Micronucleus Rat Negative

+ Hydrochloric Acid

Bacterial Mutagenicity (Ames) *Salmonella* Negative

In Vivo Micronucleus Rat Negative

Carcinogenicity

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

+ Hydrochloric Acid

IARC

Group 3 (Not Classifiable)

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties No information available.

11.2.2. Other information

SAFETY DATA SHEET

Product Name Clindamycin phosphate injection, solution (Hospira, Inc.)
Revision date 30-Jun-2022

Page 11 / 14
Version 1.01

Other adverse effects No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: Based on available data, the classification criteria are not met. Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

12.1. Toxicity

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

BENZYL ALCOHOL

Pimephales promelas (Fathead Minnow) EPA LC50 96 hours 460 - 770 mg/L
Daphnia magna (Water Flea) NPDES OECD EC50 48 Hours 230 mg/L
Pseudokirchneriella subcapitata (Green Alga) OECD EC50 72 hours 500 mg/L

12.2. Persistence and degradability

Persistence and degradability

Biodegradation: (Method, Inoculum, Biodeg Study, Result, Endpoint, Duration, Classification)

BENZYL ALCOHOL

OECD Activated sludge Ready 92 % After 28 Day(s) Ready

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment No information available.

Chemical name	PBT and vPvB assessment
BENZYL ALCOHOL	The substance is not PBT / vPvB
Sodium hydroxide	The substance is not PBT / vPvB PBT assessment does not apply
+ Hydrochloric Acid	The substance is not PBT / vPvB PBT assessment does not apply

12.6. Endocrine disrupting properties

Endocrine disrupting properties No information available.

12.7. Other adverse effects

No information available.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review

SAFETY DATA SHEET

Product Name Clindamycin phosphate injection, solution (Hospira, Inc.)
Revision date 30-Jun-2022

Page 12 / 14
Version 1.01

and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number:	Not applicable
UN proper shipping name:	Not applicable
Transport hazard class(es):	Not applicable
Packing group:	Not applicable
Environmental Hazard(s):	Not applicable
Special precautions for user:	Not applicable

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-791-2
AICS	Present

Clindamycin Phosphate

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	246-433-0

BENZYL ALCOHOL

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	202-859-9
AICS	Present

Sodium hydroxide

CERCLA/SARA Section 313 de minimus %	Not Listed
Hazardous Substances RQs	1000 lb
California Proposition 65	Not Listed
TSCA	Present
EINECS	215-185-5
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 5
	Schedule 6

+ Hydrochloric Acid

CERCLA/SARA Section 313 de minimus %	1.0 %
Hazardous Substances RQs	5000 lb
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-595-7
AICS	Present

SAFETY DATA SHEET

Product Name Clindamycin phosphate injection, solution (Hospira, Inc.)
Revision date 30-Jun-2022

Page 13 / 14
Version 1.01

Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)

Schedule 5
Schedule 6

Chemical name	French RG number	Title
BENZYL ALCOHOL 100-51-6	RG 84	-

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH Annex XVII	Substance subject to authorization per REACH Annex XIV
Sodium hydroxide - 1310-73-2	Use restricted. See item 75.	
+ Hydrochloric Acid - 7647-01-0	Use restricted. See item 75.	

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

Chemical name	Lower-tier requirements (tons)	Upper-tier requirements (tons)
+ Hydrochloric Acid - 7647-01-0	25	250

Chemical name	EU - Biocides
+ Hydrochloric Acid - 7647-01-0	Product-type 2: Disinfectants and algacides not intended for direct application to humans or animals

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

AICS - Australian Inventory of Chemical Substances

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of H-Statements referred to under section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed Acute toxicity, inhalation-Cat.4; H332 - Harmful if inhaled Serious eye damage/eye irritation-Cat.2A; H319 - Causes serious eye irritation Skin corrosion/irritation-Cat.3; H316 - Causes mild skin irritation Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction Skin corrosion/irritation-Cat.1A; Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage Acute toxicity, inhalation-Cat.3; H331 - Toxic if inhaled

Data Sources:

Publicly available toxicity information. Safety data sheets for individual ingredients. Pfizer proprietary drug development information.

SAFETY DATA SHEET

Product Name Clindamycin phosphate injection, solution (Hospira, Inc.)
Revision date 30-Jun-2022

Page 14 / 14
Version 1.01

Reason for revision Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information.

Revision date 30-Jun-2022

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.